<?xml version="1.0" encoding="UTF-8"?>
<p>The three kinds of therapeutic treatments for influenza A and B viruses include M2 inhibitors (amantadine and rimantadine), neuraminidase (NA) inhibitors (zanamivir and oseltamivir) and cap-dependent endonuclease (CEN) inhibitor (baloxavir) [
 <xref rid="pone.0238615.ref011" ref-type="bibr">11</xref>â€“
 <xref rid="pone.0238615.ref014" ref-type="bibr">14</xref>]. NA inhibitors and CEN inhibitors have both inhibitory effects on influenza A and influenza B, but M2 inhibitors act specifically on influenza A [
 <xref rid="pone.0238615.ref015" ref-type="bibr">15</xref>, 
 <xref rid="pone.0238615.ref016" ref-type="bibr">16</xref>]. Since antiviral drugs can reduce the severity of illness when administered within 48 h of the first symptoms, distinguishing between influenza A and B is critical for choosing the appropriate antiviral drug [
 <xref rid="pone.0238615.ref017" ref-type="bibr">17</xref>, 
 <xref rid="pone.0238615.ref018" ref-type="bibr">18</xref>].
</p>
